Welltower upgraded to Neutral from Underperform at BofA » 06:3511/3011/30/20
BofA analyst Joshua…
Story temporarily locked.
Welltower upgraded to Neutral from Underperform at BofA » 06:0411/3011/30/20
BofA analyst Joshua…
BofA analyst Joshua Dennerlein upgraded Welltower to Neutral from Underperform.
|Over a week ago|
Paul Singer's Elliott buys Cubic, exits AT&T in Q3 » 17:0911/1611/16/20
UNIT, CUB, T, RYAAY, SPR, DELL, CRMD, WELL, RILY, HWM, EBAY, MPC, NLSN
Paul Singer's Elliott Management disclosed in an SEC filing its holdings as of September 30, 2020. Elliott's three new buys during the third quarter included, by size of position, Uniti Group (UNIT) and Cubic (CUB). The fund exited five positions during the quarter, including by size of previous position AT&T (T), Ryanair (RYAAY), and Spirit AeroSystems (SPR). Elliott increased its stake in two holdings, namely Dell Technologies (DELL) and CorMedix (CRMD). The fund decreased its stake in two holdings, namely Welltower (WELL) and B. Riley Financial (RILY). Elliott's top holdings as of September 30, 2020, in order of size, were Dell Technologies, Howmet Aerospace (HWM), eBay (EBAY), Marathon Petroleum (MPC), and Nielsen Holdings (NLSN).
Fly Intel: Top five analyst downgrades » 09:5411/1611/16/20
SAGE, ACB, TLRY, WELL, UROV, CEA
Catch up on today's…
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Sage Therapeutics (SAGE) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Matthew Harrison saying while he believes there remains "a clear place in the treatment paradigm for zuranolone," he also believes a path to filing is currently reflected in the stock price and thinks the overall benefit may be modest when data is reported in the first quarter of 2021. 2. Aurora Cannabis (ACB) and Tilray (TLRY) downgraded to Underperform from Hold at Jefferies. 3. Welltower (WELL) downgraded to Equal Weight from Overweight at Wells Fargo with analyst Todd Stender saying he is increasingly cautious on how Welltower fundamentals can fare during another wave of COVID-19 as case counts rise across the U.S. 4. Urovant Sciences (UROV) downgraded to Neutral from Overweight at JPMorgan with analyst Raghuram Selvaraju saying the company's takeover deal by Sumitovant "appears fully valued." 5. China Eastern Airlines (CEA) downgraded to Neutral from Buy at Goldman Sachs with analyst Ben Hartwright saying China's domestic traffic recovery has been priced in, while yields are a risk. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
Welltower downgraded to Equal Weight from Overweight at Wells Fargo » 06:3211/1611/16/20
Wells Fargo analyst Todd…
Wells Fargo analyst Todd Stender downgraded Welltower to Equal Weight from Overweight with a price target of $63.50, up from $54. Stender is increasingly cautious on how Welltower fundamentals can fare during another wave of COVID-19 as case counts rise across the U.S. The analyst notes that fourth quarter is normally the seasonally slow period for the senior housing space due to the reluctance to move loved ones into assisted living facilities because of pending major holidays and believes this year will be no exception due to rising COVID cases.
Welltower downgraded to Equal Weight from Overweight at Wells Fargo » 04:4811/1611/16/20
Wells Fargo analyst Todd…
Wells Fargo analyst Todd Stender downgraded Welltower to Equal Weight from Overweight with a $63.50 price target.
Welltower downgraded to In Line from Outperform at Evercore ISI » 06:1211/1311/13/20
Evercore ISI analyst…
Evercore ISI analyst Steve Sakwa downgraded Welltower to In Line from Outperform with a $64 price target.
Jefferies upgrades Welltower to Hold on post-pandemic view » 08:0511/1011/10/20
As previously reported,…
As previously reported, Jefferies analyst Jonathan Petersen upgraded Welltower (WELL) to Hold from Underperform with a price target of $60, up from $42. While acknowledging the "pandemic is far from over," senior housing operators are learning to mitigate its impacts, occupancy declines have moderated and shares of both Welltower and peer Ventas (VTR) are trading at "reasonable multiples," Petersen tells investors. Pre-pandemic, the senior housing sector investment thesis was tied to the long-term demographic story, which still hasn't changed, Petersen added. With a vaccine getting closer, he now expects a rebound in occupancy to normal levels in the first half of 2023, which is a half a year earlier than his prior forecast.
Welltower upgraded to Hold from Underperform at Jefferies » 04:4411/1011/10/20
Jefferies analyst Jonathan Petersen upgraded Welltower to Hold from Underperform with a $60 price target.
|Over a month ago|
Welltower downgraded to Neutral after recent rally at Mizuho » 06:5810/1610/16/20
Mizuho analyst Omotayo…
Mizuho analyst Omotayo Okusanya downgraded Welltower to Neutral from Buy with a price target of $57, up from $51. Investors are increasingly pricing in the scenario where a COVID vaccine is discovered before year-end and senior housing receives additional stimulus from the federal government, Okusanya tells investors in a research note. The analyst believes healthcare real estate investment trust stocks will pull back if there are delays in either of these two catalysts, and especially if COVID cases keep spiking into the winter season. Further, a recovery in senior housing fundamentals may be slower than anticipated as senior housing occupancy is unlikely to return to pre-COVID levels until at least early 2022, says the analyst. As a result, he believes earnings growth will likely be relatively weak in 2021 and that further multiple expansion seems unlikely.